

Olubukola T Idoko

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6607674/publications.pdf>

Version: 2024-02-01

36
papers

894
citations

623734

14
h-index

501196

28
g-index

37
all docs

37
docs citations

37
times ranked

1546
citing authors

#	ARTICLE	IF	CITATIONS
1	Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans. <i>New England Journal of Medicine</i> , 2011, 364, 2293-2304.	27.0	155
2	Dynamic molecular changes during the first week of human life follow a robust developmental trajectory. <i>Nature Communications</i> , 2019, 10, 1092.	12.8	151
3	Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of <i>Streptococcus pneumoniae</i> in infants: A phase 2, randomized, controlled, observer-blind study. <i>Vaccine</i> , 2017, 35, 2531-2542.	3.8	71
4	Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: An open-label randomized controlled trial. <i>Tuberculosis</i> , 2014, 94, 564-578.	1.9	58
5	Effect on nasopharyngeal pneumococcal carriage of replacing PCV7 with PCV13 in the Expanded Programme of Immunization in The Gambia. <i>Vaccine</i> , 2015, 33, 7144-7151.	3.8	48
6	A scorecard of progress towards measles elimination in 15 west African countries, 2001â€“19: a retrospective, multicountry analysis of national immunisation coverage and surveillance data. <i>The Lancet Global Health</i> , 2021, 9, e280-e290.	6.3	28
7	Tracking coverage, dropout and multidimensional equity gaps in immunisation systems in West Africa, 2000â€“2017. <i>BMJ Global Health</i> , 2019, 4, e001713.	4.7	26
8	Antibody kinetics following vaccination with MenAfriVac: an analysis of serological data from randomised trials. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 327-336.	9.1	25
9	Impact, Challenges, and Future Projections of Vaccine Trials in Africa. <i>American Journal of Tropical Medicine and Hygiene</i> , 2013, 88, 414-419.	1.4	24
10	Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines â€“ A phase II, randomised, observer-blind study in Gambian infants. <i>Vaccine</i> , 2019, 37, 2586-2599.	3.8	19
11	Increased Disease due to <i>Haemophilus influenzae</i> Type b. <i>Pediatric Infectious Disease Journal</i> , 2015, 34, e107-e112.	2.0	18
12	Antibody Persistence at 1 and 4 Years Following a Single Dose of MenAfriVac or Quadrivalent Polysaccharide Vaccine in Healthy Subjects Aged 2â€“29 Years. <i>Clinical Infectious Diseases</i> , 2015, 61, S521-S530.	5.8	17
13	Prospects and challenges with introduction of a mono-valent meningococcal conjugate vaccine in Africa. <i>Vaccine</i> , 2009, 27, 2023-2029.	3.8	15
14	Development and Use of a Serum Bactericidal Assay Using Pooled Human Complement To Assess Responses to a Meningococcal Group A Conjugate Vaccine in African Toddlers. <i>Vaccine Journal</i> , 2014, 21, 755-761.	3.1	15
15	Meningococcal Group C and W135 Immunological Hyporesponsiveness in African Toddlers. <i>Vaccine Journal</i> , 2011, 18, 1492-1496.	3.1	14
16	The impact of pre-existing antibody on subsequent immune responses to meningococcal A-containing vaccines. <i>Vaccine</i> , 2014, 32, 4220-4227.	3.8	14
17	Community Perspectives Associated With the African PsA-TT (MenAfriVac) Vaccine Trials. <i>Clinical Infectious Diseases</i> , 2015, 61, S416-S421.	5.8	14
18	Lessons in participant retention in the course of a randomized controlled clinical trial. <i>BMC Research Notes</i> , 2014, 7, 706.	1.4	13

#	ARTICLE	IF	CITATIONS
19	Antibody Persistence 1â€“5 Years Following Vaccination With MenAfriVac in African Children Vaccinated at 12â€“23 Months of Age. <i>Clinical Infectious Diseases</i> , 2015, 61, S514-S520.	5.8	13
20	Zika Virus in West Africa: A Seroepidemiological Study between 2007 and 2012. <i>Viruses</i> , 2020, 12, 641.	3.3	13
21	The burden of viral respiratory infections in young children in low-resource settings. <i>The Lancet Global Health</i> , 2020, 8, e454-e455.	6.3	13
22	Bacille Calmette-GuÃ©rin vaccine reprograms human neonatal lipid metabolism in vivo and in vitro. <i>Cell Reports</i> , 2022, 39, 110772.	6.4	13
23	Clinical Protocol for a Longitudinal Cohort Study Employing Systems Biology to Identify Markers of Vaccine Immunogenicity in Newborn Infants in The Gambia and Papua New Guinea. <i>Frontiers in Pediatrics</i> , 2020, 8, 197.	1.9	12
24	Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine (PCV13) formulated with 2-phenoxyethanol in multidose vials given with routine vaccination in healthy infants: An open-label randomized controlled trial. <i>Vaccine</i> , 2017, 35, 3256-3263.	3.8	11
25	Antibody responses to yellow fever vaccine in 9 to 11-month-old Malian and Ghanaian children. <i>Expert Review of Vaccines</i> , 2019, 18, 867-875.	4.4	11
26	Ethical Challenges and Lessons Learned During the Clinical Development of a Group A Meningococcal Conjugate Vaccine. <i>Clinical Infectious Diseases</i> , 2015, 61, S422-S427.	5.8	9
27	Acceptance of multiple injectable vaccines in a single immunization visit in The Gambia pre and post introduction of inactivated polio vaccine. <i>Vaccine</i> , 2016, 34, 5034-5039.	3.8	8
28	Human Complement Bactericidal Responses to a Group A Meningococcal Conjugate Vaccine in Africans and Comparison to Responses Measured by 2 Other Group A Immunoassays. <i>Clinical Infectious Diseases</i> , 2015, 61, S554-S562.	5.8	7
29	Recall and decay of consent information among parents of infants participating in a randomized controlled clinical trial using an audio-visual tool in The Gambia. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2185-2191.	3.3	7
30	Plasma Adenosine Deaminase (ADA)-1 and -2 Demonstrate Robust Ontogeny Across the First Four Months of Human Life. <i>Frontiers in Immunology</i> , 2021, 12, 578700.	4.8	7
31	<i>Neisseria meningitidis</i> Group A IgG1 and IgG2 Subclass Immune Response in African Children Aged 12â€“23 Months Following Meningococcal Vaccination. <i>Clinical Infectious Diseases</i> , 2015, 61, S563-S569.	5.8	5
32	Serological Protection 5â€“6 Years Post Vaccination Against Yellow Fever in African Infants Vaccinated in Routine Programmes. <i>Frontiers in Immunology</i> , 2020, 11, 577751.	4.8	5
33	Conducting clinical research in a resource-constrained setting: lessons from a longitudinal cohort study in The Gambia. <i>BMJ Global Health</i> , 2021, 6, e006419.	4.7	4
34	Ontogeny of plasma cytokine and chemokine concentrations across the first week of human life. <i>Cytokine</i> , 2021, 148, 155704.	3.2	4
35	A cloud-based bioinformatic analytic infrastructure and Data Management Core for the Expanded Program on Immunization Consortium. <i>Journal of Clinical and Translational Science</i> , 2021, 5, e52.	0.6	3
36	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Africa: Current Considerations and Future Projections. <i>Clinical Infectious Diseases</i> , 2022, 75, S136-S140.	5.8	3